Medicenna Therapeutics (MDNAF) SEC Filings

Medicenna Therapeutics Corp., a Canadian biotechnology company, is conducting a U.S. private offering of units under Rule 506(b) of Regulation D. Each unit consists of one common share and one-half of a common share purchase warrant; each whole warrant allows purchase of one share at an exercise price of C$0.65 for three years following May 28, 2026.

The company reports $253,458 USD in securities sold, with an additional $2,089,942 USD potentially payable to Medicenna if U.S. investors exercise the warrants. No finders' fees are being paid, and proceeds may be used in the ordinary course, including salaries for certain executive officers and directors.